US EditionHepion names new interim CEO, shifts to diagnostic innovation
Summary by NJBIZ
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Hepion names new interim CEO, shifts to diagnostic innovation
The basics: Dr. Kaouthar Lbiati named interim CEO of Hepion Company pivots to precision diagnostics for celiac, liver cancer Former liver disease drug Rencofilstat sold to Panetta Partners Hepion Pharmaceuticals Inc. is undergoing another CEO transition as Dr. Kaouthar Lbiati steps into the interim role, the Edison-based biopharmaceutical company announced June 16. Lbiati succeeds John Brancaccio, who also served in an interim chief executive …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
